Results 41 to 50 of about 2,327,860 (219)
Cerebrovascular Diseases Extra, 2021 Increasing incidence of stroke and lack of infrastructure in both urban and rural areas needs immediate attention in Pakistan. There is a high proportion of young stroke with poor stroke outcomes.
Anjum Farooq +2 more
doaj +1 more source
Thrombolysis With Recombinant Tissue Plasminogen Activator in 7 Children
Clinical and Applied Thrombosis/Hemostasis, 2012 The information about the thromboembolic events, the optimal treatment choice, the dose, and duration of antithrombotic therapy in children are limited. More clinical data are required. Recombinant tissue plasminogen activator (r-tPA) is increasingly used in pediatric thrombosis.
Bostan, ÖZLEM MEHTAP +4 more
openaire +3 more sources
SAGE Open Medical Case Reports, 2020 The objective of this case series is the evaluation of the efficacy and visual outcomes after displacement of subretinal hemorrhage using intravitreal injection of recombinant tissue plasminogen activator, expansile gas, and in some cases an anti ...
Athanasios Karamitsos +9 more
doaj +1 more source
IGF2 knockout reduces but does not abolish osteosarcoma growth in vitro and in vivo
FEBS Open Bio, EarlyView.To test whether endogenous IGF2 promotes osteosarcoma growth, IGF2 was knocked out in Saos2 cells via CRISPR‐Cas9. KO cells showed reduced proliferation in vitro, and knockout xenografts in mice reached only ~25% of wild‐type tumor volume. Insulin‐like growth factor 2 (IGF2) is implicated in osteosarcoma, but direct functional evidence of its role is ...
Shun Yao, Marco Archetti
wiley +1 more source
Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary care centre [PDF]
, 2012 Includes abstract.Includes bibliographical references.Stroke is an important cause of death and disability in sub-Saharan Africa. Recombinant tissue plasminogen activator (tPA) thrombolysis is effective in treating acute ischaemic stroke, but may not be ...
Wasserman, Sean
core +1 more source
Long-term stability of recombinant tissue plasminogen activator at -80 C
BMC Research Notes, 2009 Background Recombinant tissue plasminogen activator (tPA) is a thrombolytic widely used clinically in the treatment of acute thrombotic disease such as ischemic stroke, myocardial infarction, and deep venous thrombosis.
Sperling Matthew +2 more
doaj +1 more source
Recombinant tissue plasminogen activator for acute ischemic stroke
Neurosciences, 2002 Stroke is a leading cause of serious and long-term disability and death worlwide, with approximately 750,000 strokes occuring annually in the United States of America. The risk of stroke doubles each decade for people over 55 years. Cerebral angiography conducted soon after the onset of stroke demonstrates arterial occlusion in 70%-80% of cases ...
Amira R, Al-Buhairi, Mohammed M, Jan
openaire +3 more sources
Advanced Robotics Research, EarlyView.Micro‐ and nanorobots for targeted thrombolysis. This perspective elaborates on the clinical indication of blood clot disorders and current limitations for treatment. As a novel, alternative solution, micro‐ and nanorobots can be used to treat and break down thrombi.
Joshua M. Mesfin +3 more
wiley +1 more source
Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells. [PDF]
, 2012 Mesothelial cells are critical in the pathogenesis of post-surgical intraabdominal adhesions as well as in the deterioration of the peritoneal membrane associated with long-term peritoneal dialysis.
Elfriede Noessner +54 more
core +2 more sources
Intravenous thrombolysis in ischemic stroke: clinical predictors of efficacy and safety
Анналы клинической и экспериментальной неврологии, 2019 Introduction. Systemic thrombolysis with recombinant tissue plasminogen activator is the gold standard of reperfusion therapy, having the maximum level of evidence in European and North American guidelines for the treatment of patients with acute ...
Maksim A. Domashenko +2 more
doaj +1 more source